S&P REITERATES BUY OPINION ON SHARES OF DYAX CORP (Standard & Poor's)
DYAX reports strategic partnership with Sigma-Tau SpA to develop and commercialize DX-88 for hereditary angioedema in ex-U.S. territories including Europe, North Africa, Middle East and Russia. DYAX will receive $5M in upfront payments, and will be eligible for over $100M in milestones and 41% sales royalties. Despite modest upfront proceeds, we view commercial economic terms to DYAX favorably, and see development cost sharing for new studied indications easing DYAX's expense burden, as it advances early stages of drug's U.S. launch. We keep our target price at $6.00.